1. Introduction

Designer Embryo Accountability refers to the legal, ethical, scientific and institutional responsibility arising from the creation, selection, genetic modification or manipulation of human embryos to influence their inherited characteristics.

The concept is closely associated with reproductive biotechnology, genetic engineering, preimplantation genetic testing (PGT), CRISPR-Cas9 gene editing, embryo screening and reproductive medicine.

A designer embryo may involve:

Selecting embryos to avoid inherited genetic diseases.

Screening embryos for particular genetic characteristics.

Editing embryonic DNA to eliminate disease-associated mutations.

Attempting to select non-medical traits, such as physical appearance, intelligence or other characteristics.

Creating embryos with deliberately modified genetic characteristics for reproductive purposes.

The central legal question is:

Who should be held accountable when scientists, fertility clinics, biotechnology companies, parents or regulatory authorities create or select genetically modified embryos, particularly when the consequences may affect future generations?

Designer embryo accountability therefore concerns not only individual consent but also scientific responsibility, children's rights, genetic privacy, public health, reproductive autonomy, discrimination and intergenerational justice.

An important distinction must be maintained: selecting an embryo through genetic testing is not the same as directly modifying its DNA. Their scientific risks and legal implications are different.

2. Meaning and Scope of Designer Embryo Accountability

Designer embryo accountability establishes responsibility for decisions made throughout the reproductive biotechnology process.

Its principal dimensions include:

Scientific accountability: Researchers must demonstrate the safety, reliability and scientific validity of embryo-related procedures.

Clinical accountability: Fertility clinics and medical professionals must follow professional standards and disclose material risks.

Parental accountability: Intended parents must make informed reproductive decisions without being misled about genetic technologies.

Corporate accountability: Biotechnology companies must be responsible for misleading claims, defective technologies and negligent practices.

Regulatory accountability: Governments must establish effective licensing, monitoring and enforcement systems.

Intergenerational accountability: Decisions affecting inheritable genetic material must consider possible consequences for future generations.

Human-rights accountability: Genetic technologies must respect dignity, equality, privacy and reproductive freedom.

The doctrine is particularly important because changes to an embryo's germline may potentially be inherited by subsequent generations.

3. Legal Framework in India

India does not have a single comprehensive statute specifically titled Designer Embryo Accountability. However, several laws regulate important aspects of embryo creation, genetic testing, reproductive treatment and scientific research.

A. Assisted Reproductive Technology (Regulation) Act, 2021

The Assisted Reproductive Technology (Regulation) Act, 2021 is a central piece of legislation.

Important provisions include:

Section 25 – Preimplantation Genetic Diagnosis

Preimplantation genetic testing may be used to screen human embryos for known, pre-existing, heritable or genetic diseases only.

Embryo donation for research is subject to the statutory conditions, including the consent of the commissioning couple or woman and the specified disease-related requirements.

This provision is particularly significant because it establishes a medical purpose for embryo screening rather than permitting unrestricted genetic selection.

India Code+1

Section 26 – Sex Selection

This provision prohibits clinics from offering a child of predetermined sex, subject to the limited statutory exception for diagnosis, prevention or treatment of sex-linked disorders.

It is relevant to designer embryo accountability because it prevents reproductive technology from being used for prohibited sex selection.

India Code

Section 30 – Research on Human Gametes and Embryos

The Act prohibits the use of human gametes and embryos, or their transfer outside India, for research. Research conducted within India must comply with the prescribed legal framework.

IndiaCode

B. Pre-Conception and Pre-Natal Diagnostic Techniques Act, 1994

The Pre-Conception and Pre-Natal Diagnostic Techniques (Prohibition of Sex Selection) Act, 1994 is important for controlling sex selection and preventing the misuse of reproductive and diagnostic technologies.

Its objectives include:

Prohibiting sex selection before or after conception.

Regulating prenatal diagnostic techniques.

Preventing discrimination against female children.

Controlling misuse of genetic and reproductive diagnostic services.

The Act must be read alongside the ART Act when evaluating embryo-related sex selection.

C. Constitution of India

Several constitutional provisions provide the foundation for accountability.

Article 21 is especially important because genetic decisions may affect personal identity, reproductive autonomy, bodily integrity and the dignity of future children.

D. Indian Council of Medical Research Guidelines

The Indian Council of Medical Research (ICMR) guidelines and applicable national research-ethics requirements provide standards for human biomedical research.

They are relevant to:

Informed consent.

Independent ethical review.

Scientific validity.

Protection of research participants.

Risk-benefit assessment.

Responsible handling of biological material.

Their application must be distinguished from statutory prohibitions: ethical approval cannot authorize an activity that legislation prohibits.

4. Important Case Laws Relating to Designer Embryo Accountability

There is no universally established judicial doctrine specifically called Designer Embryo Accountability. Nevertheless, several important judgments establish legal principles that can be applied to embryo selection, genetic manipulation, reproductive autonomy and scientific responsibility.

1. Suchita Srivastava v. Chandigarh Administration (2009) 9 SCC 1

Court: Supreme Court of India.

Legal principle: Reproductive autonomy is part of personal liberty under Article 21.

The Supreme Court recognised that reproductive choices include the right to make decisions concerning reproduction and bodily integrity.

Relevance to designer embryos:

The judgment provides a constitutional foundation for reproductive decision-making. Parents should receive accurate information and retain meaningful autonomy in lawful reproductive decisions.

However, reproductive autonomy does not automatically create an unrestricted right to genetically design or modify embryos.

2. Justice K.S. Puttaswamy v. Union of India (2017) 10 SCC 1

Court: Supreme Court of India.

Legal principle: Privacy is a fundamental right under Article 21.

The Court recognised informational privacy, decisional autonomy and personal dignity as important aspects of constitutional privacy.

Relevance to designer embryos:

Genetic information can reveal highly personal information about individuals and their biological relatives.

Consequently:

Genetic information must be protected against unauthorised disclosure.

Fertility clinics must maintain confidentiality.

Genetic data should not be commercially exploited without lawful justification.

Parents should be informed about genetic-data storage and use.

Future children have important interests in the protection of their genetic identity.

This judgment is particularly relevant to genetic-data accountability.

3. Samira Kohli v. Dr. Prabha Manchanda (2008) 2 SCC 1

Court: Supreme Court of India.

Legal principle: Valid medical consent must be informed and voluntary.

The Court explained the requirements of informed consent and the limits of medical treatment without proper authorisation.

Relevance to designer embryos:

Before undertaking embryo screening or other reproductive interventions, medical professionals should explain:

The purpose of the procedure.

Scientific limitations.

Potential medical risks.

Possible consequences of genetic findings.

Available alternatives.

Financial and treatment implications.

A patient cannot be considered to have given meaningful consent merely by signing a standard clinic form.

4. Costa and Pavan v. Italy (2012), Application No. 54270/10

Court: European Court of Human Rights.

Legal principle: Access to embryo screening for avoiding serious hereditary disease can fall within the protection of private and family life under Article 8 of the European Convention on Human Rights.

The applicants were carriers of cystic fibrosis and wanted to use IVF and preimplantation genetic diagnosis to avoid transmitting the disease.

The Court found a violation of Article 8 because Italian law prohibited embryo screening while permitting termination of an affected pregnancy, creating an inconsistency.

Relevance to designer embryos:

The judgment distinguishes medically justified genetic screening from unrestricted genetic enhancement.

It supports reproductive autonomy in the context of avoiding serious hereditary disease, but does not establish a general right to genetically engineer embryos.

HUDOC+1

5. Evans v. United Kingdom (2007), Application No. 6339/05

Court: European Court of Human Rights, Grand Chamber.

Legal principle: Reproductive autonomy must be balanced against the reproductive rights of other individuals.

The case concerned frozen embryos created through IVF. Following the breakdown of the relationship, one partner withdrew consent to their continued use.

The Court upheld the UK's consent requirements.

Relevance to designer embryos:

The decision is important for determining:

Who controls embryos created through IVF.

Whether consent can be withdrawn.

Whether genetic reproductive decisions require continuing agreement.

How competing reproductive interests should be balanced.

It demonstrates that the creation of an embryo does not eliminate the legal significance of consent.

6. Davis v. Davis (1992), 842 S.W.2d 588

Court: Supreme Court of Tennessee, United States.

Legal principle: Disputes concerning frozen embryos require consideration of the parties' preferences, prior agreements and competing reproductive interests.

The dispute arose after divorce, when one partner wanted the embryos implanted and the other opposed becoming a parent.

The court developed a balancing approach, generally giving considerable weight to the interest in avoiding unwanted procreation.

Relevance to designer embryos:

This judgment provides guidance on embryo ownership disputes, consent, reproductive control and the legal consequences of decisions made before embryo creation.

Justia Law+1

7. Kass v. Kass (1998), 91 N.Y.2d 554

Court: New York Court of Appeals.

Legal principle: Prior agreements concerning the disposition of frozen embryos can determine how disputes are resolved.

The parties had entered an agreement concerning the possible donation of their embryos for research. The court gave effect to that agreement.

Relevance to designer embryos:

The decision demonstrates the importance of:

Written reproductive agreements.

Clear consent procedures.

Embryo-storage conditions.

Research-use restrictions.

Prior decisions concerning unused embryos.

It also highlights the importance of transparency before genetic procedures are undertaken.

Justia Law+1

8. He Jiankui Gene-Edited Babies Case (2019)

Court: Nanshan District People's Court, Shenzhen, China.

Nature: Criminal prosecution involving reproductive human gene editing.

This is one of the most important real-world legal proceedings concerning designer embryos.

In 2018, Chinese scientist He Jiankui announced that he had used CRISPR-Cas9 technology to modify human embryos by altering the CCR5 gene, with the stated intention of reducing susceptibility to HIV infection.

The experiment resulted in the birth of genetically edited children.

In December 2019, the Shenzhen court convicted He Jiankui and two collaborators of illegal medical practice.

He received:

Three years' imprisonment.

A fine of three million yuan.

The court found that the researchers had violated medical regulations and ethical requirements, including falsifying ethical-review documentation.

English.news.cn+1

Relevance to designer embryo accountability:

This proceeding demonstrates that:

Scientists can face criminal responsibility for unlawful reproductive gene editing.

Fabricated ethical approval can attract serious legal consequences.

Scientific innovation does not override medical licensing requirements.

The birth of genetically modified children creates significant long-term responsibilities.

Researchers cannot treat future children as experimental subjects without adequate safeguards.

Legal significance: This was a criminal conviction, not a general judicial ruling establishing an international prohibition on all embryo gene editing.

5. International Legal and Ethical Principles

A. Human Genome Editing Recommendations, 2021

The World Health Organization (WHO) published Human Genome Editing: Recommendations in 2021.

The recommendations address:

International cooperation.

Human genome-editing registries.

Oversight of clinical research.

Unethical and unregistered research.

Medical tourism involving genome editing.

Intellectual property.

Public engagement and education.

The WHO framework recognises that heritable genetic changes can affect future generations and require stronger governance mechanisms.

World Health Organization+2

B. Human Dignity and Genetic Non-Discrimination

Designer embryo technology raises important questions concerning equality.

For example, if wealthy parents can purchase genetic enhancement services, society may experience unequal access to reproductive technologies.

Potential consequences include:

Genetic discrimination.

Social inequality.

Commercialisation of reproduction.

Stigmatisation of disabilities.

Discrimination against naturally conceived children.

Development of genetic preferences based on social stereotypes.

The legal challenge is to protect medical innovation without creating a system in which human worth is determined by genetic characteristics.

C. Future Generations and Intergenerational Justice

Germline modification is different from ordinary medical treatment because genetic changes may be transmitted to descendants.

This creates a problem of consent.

An embryo cannot independently consent to genetic modification, and future generations cannot participate in decisions made before their birth.

Therefore, researchers and regulators must assess:

Long-term genetic consequences.

Unintended mutations.

Off-target editing.

Potential hereditary diseases.

Effects on reproductive health.

Scientific uncertainty.

The WHO framework provides an important foundation for addressing these risks.

World Health Organization+1

6. Different Forms of Legal Liability

Designer embryo accountability may involve several forms of legal liability.

A. Medical Negligence

A fertility specialist may face liability where negligent embryo testing, inaccurate genetic interpretation or improper embryo handling causes legally recognised injury.

For example, a clinic may fail to disclose a known limitation of a genetic screening procedure.

B. Criminal Liability

Criminal responsibility may arise where individuals deliberately conduct prohibited reproductive procedures, falsify research approvals or violate applicable medical regulations.

The He Jiankui prosecution illustrates this possibility.

C. Corporate Accountability

Biotechnology companies may face liability for:

Misrepresenting genetic testing accuracy.

Selling unvalidated embryo-editing technologies.

Concealing known scientific risks.

Making misleading genetic enhancement claims.

Mishandling sensitive reproductive information.

D. Institutional Accountability

Hospitals and research institutions should maintain:

Independent ethics committees.

Scientific-review procedures.

Research documentation.

Genetic-data security.

Qualified medical personnel.

Mechanisms for reporting adverse events.

7. Major Ethical and Constitutional Challenges

1. Right to genetic identity

Whether a child has an interest in knowing the circumstances and nature of genetic modifications affecting their biological identity.

2. Right to an open future

Whether parents and researchers should have unlimited authority to determine the genetic characteristics of a future child.

3. Disability discrimination

Whether selecting against certain genetic conditions may reinforce discriminatory attitudes towards persons living with disabilities.

4. Genetic inequality

Whether genetic enhancement will become an expensive service available primarily to economically privileged families.

5. Commercial exploitation

Whether biotechnology businesses should be permitted to market genetic enhancement as a guaranteed means of producing superior children.

6. Intergenerational responsibility

Who should bear responsibility when an inherited genetic modification produces an adverse effect several generations later?

7. Regulatory jurisdiction

How should authorities regulate clinics that perform prohibited procedures in one country and offer their services to patients from another?

8. Proposed Framework for Designer Embryo Accountability

A comprehensive accountability system should contain the following safeguards.

A particularly important distinction should be made between:

Therapeutic embryo selection: Screening to avoid a serious inherited disease.

Genetic enhancement: Attempting to produce preferred physical, cognitive or other characteristics.

Germline modification: Directly altering genetic material in a way that may be inherited.

These activities should not be treated as legally or ethically equivalent.

9. Important Research and Judicial Questions

The development of designer embryo accountability raises several unresolved legal questions:

Can parents be held responsible for deliberately selecting embryos for non-medical enhancement?

Can a child bring a legal claim for injury resulting from an inherited genetic modification?

Can biotechnology companies be held responsible for genetic modifications that produce delayed adverse effects?

Should germline editing for reproductive purposes be treated differently from embryo research that does not result in pregnancy?

Can genetic enhancement violate constitutional equality?

Who is responsible for monitoring genetically modified children after birth?

Can future generations claim compensation for inherited genetic injuries?

Should international law establish common standards for reproductive gene editing?

These questions are especially significant because existing reproductive laws and conventional medical-negligence principles may not adequately address every consequence of heritable genetic modification.

10. Conclusion

Designer Embryo Accountability represents an emerging area of biotechnology law concerned with the responsible use of genetic technologies in human reproduction.

The Indian legal framework provides important safeguards through the Assisted Reproductive Technology (Regulation) Act, 2021, particularly Sections 25, 26 and 30, alongside constitutional principles, the PCPNDT Act and applicable medical-research requirements.

The judgments in Suchita Srivastava, Puttaswamy, Samira Kohli, Costa and Pavan, Evans, Davis and Kass provide important principles concerning reproductive autonomy, privacy, informed consent and embryo-related disputes.

The He Jiankui prosecution provides a particularly significant example of criminal accountability for unlawful reproductive gene editing.

Central legal proposition

Scientific freedom in reproductive biotechnology must operate within the limits of human dignity, informed consent, genetic privacy, equality, public safety and intergenerational responsibility.

The ultimate objective should not be to prohibit legitimate medical progress, but to ensure that technological power over human reproduction is exercised lawfully, transparently and responsibly.

11. Important References for Further Legal Research

Assisted Reproductive Technology (Regulation) Act, 2021 – India.

Pre-Conception and Pre-Natal Diagnostic Techniques Act, 1994 – India.

Constitution of India – Articles 14 and 21.

WHO, Human Genome Editing: Recommendations (2021).

WHO, Human Genome Editing: A Framework for Governance (2021).

Suchita Srivastava v. Chandigarh Administration (2009) 9 SCC 1.

Justice K.S. Puttaswamy v. Union of India (2017) 10 SCC 1.

Samira Kohli v. Dr. Prabha Manchanda (2008) 2 SCC 1.

Costa and Pavan v. Italy (2012).

Evans v. United Kingdom (2007).

Davis v. Davis (1992), 842 S.W.2d 588.

Kass v. Kass (1998), 91 N.Y.2d 554.

Shenzhen Nanshan District People's Court proceedings concerning He Jiankui (2019).

Important academic qualification: There is no established Indian Supreme Court judgment directly deciding the legality of creating designer babies through heritable human embryo gene editing. The Indian judgments discussed above are relevant by analogy, while the Chinese proceedings provide a direct example of criminal enforcement. This distinction is important in legal dissertations and research publications.